Industry Webinars

AUC for Cardiac PET and How to Incorporate Into Your Practice

Watch Now

Sponsored By: CDL Nuclear Technologies


Featured Speakers: 

Dr. Vasken Dilsizian

Dr. Dilsizian has been a professor of radiology and medicine at the University of Maryland School of Medicine since 2001, and chief of the division of nuclear medicine since 2007.  He served as the President of the Society of Nuclear Medicine and Molecular Imaging (2019-2020).  He received the Hermann Blumgart Award for his innumerable contributions to the science of nuclear cardiology. He served as the Vice-Chair of the Nuclear Regulatory Commission (NRC) Advisory Committee on the Medical Uses of Isotopes (ACMUI; 2021-2022), and a member of the Board of Scientific Counselors of the National Institutes of Health, Clinical Center (2018-2022). His has published over 280 original, peer-reviewed manuscripts and invited editorials/articles, 12 books, and 51 book chapters.

Dr. George Basu

Dr. Basu received his undergraduate degree from McGill University, B.Sc. in Physiology.  He then, completed his medical degree at the Ohio State University and did heart failure research at the Cleveland Clinic.  He completed Internal Medicine training at Baylor College of Medicine and general and interventional cardiology at the Texas Heart Institute.  He’s been part of Houston Cardiovascular Associates and an associate professor at the University of Texas-Houston since finishing training in 2006.  In addition to running a clinical practice, he is currently the chair of the clinical governance board of Houston Cardiovascular.  He is Strategic Chief Medical Officer of US Heart and Vascular.  He has leadership positions on QM committees at Houston Methodist hospital and the alternate payment committee of the Texas Medical Association.  

Learning Objectives:

  1. Outline the clinical benefit and appropriate use criteria for the utilization of Cardiac PET
  2. Speak to the clinical and economic impact Cardiac PET has had within a practice and share how they implemented PET as a new modality for their patients​

This program is sponsored by CDL Nuclear Technologies.

Information contained herein regarding any specific person, commercial product process, or service by trade name, trademark, manufacturer, or otherwise, does not constitute or imply its endorsement, recommendation, or favoring by the American Society of Nuclear Cardiology (ASNC), its directors or employees.